Dosing and Administration

CUVITRU® can be infused at the fastest rates or highest volumes with the fewest needlesticks of any SCIG, without sacrificing tolerability1,2

Clock icon.

How fast?

The median duration of once-weekly infusions was <1 hour (0.95 hours; range: 0.2-6.4 hours) in the North American clinical study.

  • CUVITRU may allow delivery of a full week’s dose in <15 minutes–with even shorter durations possible with more frequent dosing*
  • Approximately 94% of infusions were completed within 2 hours3

*If a patient is 75 kg (165 lb) and has been prescribed 36 g of IVIG per month, you could switch your patient to 12 g of CUVITRU weekly. After the first 2 infusions, subsequent infusions of CUVITRU could be completed in 15 minutes at a rate of 60 mL/h/site using 4 sites simultaneously.

Syringe icon.

What did this mean to patients?

  • Infuse at rates up to 60 mL/h/site in up to 4 sites simultaneously for a maximum total of 240 mL/h. Infuse first 2 infusions at 10 to 20 mL/h/site
  • With the highest infusion volume (60 mL/h/site, as tolerated) compared to any other conventional SCIG option, a daily, weekly, or every-other-week infusion schedule is possible for your patients 
  • Your patients can create a treatment plan that meets their schedule

Infuse first 2 infusions at 10 to 20 mL/h/site.

1 - 2 infusion sites written inside of an orange circle.

How few?

84.9% (N=4314) of infusions were administered using only 1 or 2 infusion sites (18.5%=1 site; 66.4%=2 sites) in the North American clinical study.

  • Infuse weekly in <1 hour in 1-2 sites
  • The use of more infusion sites may be beneficial for patients who want to reduce the volume administered per site or overall infusion duration

SCIG=subcutaneous immune globulin.

Flexible administration
See how CUVITRU provides patients options.

Getting started with CUVITRU

To see important information for starting your patients on CUVITRU, explore the tabs below.

Explore administration combinations

Use the infusion calculator to determine CUVITRU administration parameter combinations for your patients based on needlesticks and frequency of infusions, and help your patients achieve CUVITRU’s maximum infusion rate by selecting the proper supplies.

Infusion calculator

Choose from the following parameters to find the right dosing plan for you and your patient.

Calendar icon.

SCIG dose



Needlesticks 1 2 3 4
Milliliter icon drop.


per SCIG
20% infusion

The dosing calculator is meant to be used as a tool to help HCPs make informed decisions about dosing. Takeda is not making dosing recommendations.

Determine dosage range

To determine the dosage ranges for a patient, select the weight closest to the patient’s weight in the window on the left. Dosage ranges will appear in grams. See Full Prescribing Information for additional dosage recommendations. A conversion factor of 2.2046 lb/kg is used to convert the patient’s weight to kilograms. The values displayed are rounded to the nearest decimal point.

What is the
patient's weight?

lb or kg

Dosage range to be prescribed every 3-4 weeks or per patient needs

300 mg/kg =
400 mg/kg =
500 mg/kg =
600 mg/kg =

This calculator does not represent every possible weight calculation. Weights begin as 88 lb and increase in 4 lb increments to 288 lb.

Select CUVITRU vial combinations based on dosage

CUVITRU is available in 1 g, 2 g, 4 g, 8 g, and 10 g vials of IG 20%. The dose must be rounded up or down, based on the physician’s clinical judgement.

IV bag icon.

View examples of 2 patients’ infusion sites from pre-infusion to 24 hours after.

Volume infused per physician guidance based on patient’s specific clinical condition. It may be different for other patients.

Patient No. 1: Male, age 59 

  • 60 mL infusion  in 1 site of the abdomen
  • Infused at maximum rate of 60 mL/h/site

Patient No. 2: Female, age 14

  • 40 mL infusion in 1 site of the thigh
  • Infused at rate of 40 mL/h/site

*1-hour infusion time.

Beginning patients on CUVITRU in a few steps 

Learn about starting patients on CUVITRU


  1. CUVITRU. Prescribing information. Baxalta US Inc., 2021.
  2. Suez D, Stein M, Gupta S, et al. Efficacy, safety, and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America. J Clin Immunol. 2016;36(7):700-712.
  3. Data on file. Takeda US Inc. 2015.